Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  European journal of medicinal chemistry

• Publication date

  2018-02-10

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejmech.2018.01.002PMID 29407591
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The replacement of the 2-methoxy substituent of N-((6,6-diphenyl-1,4-dioxan-2-yl)methyl)-2-(2-methoxyphenoxy)ethan-1-amine improves the selectivity for 5-HT1A receptor over α1-adrenoceptor and D2-like receptor subtypes.

  2017cited by this paper
• The effects of a 5-HT5A receptor antagonist in a ketamine-based rat model of cognitive dysfunction and the negative symptoms of schizophrenia.

  2016cited by this paper
• Altering the course of schizophrenia: progress and perspectives

  2016cited by this paper
• N1-Azinylsulfonyl-1H-indoles: 5-HT6 Receptor Antagonists with Procognitive and Antidepressant-Like Properties.

  2016cited by this paper
• Improvement of ketamine-induced social withdrawal in rats: the role of 5-HT7 receptors

  2015cited by this paper
• What Can Crystal Structures of Aminergic Receptors Tell Us about Designing Subtype-Selective Ligands?

  2015cited by this paper
• Inhibition of human cytochrome P450 isoenzymes by a phenothiazine neuroleptic levomepromazine: An in vitro study

  2015cited by this paper
• 1-Aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats

  2014cited by this paper
• The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia

  2014cited by this paper
• Effects of the Selective 5-HT7 Receptor Antagonist SB-269970 and Amisulpride on Ketamine-Induced Schizophrenia-like Deficits in Rats

  2013cited by this paper
• Future directions for serotonin and antidepressants.

  2013cited by this paper
• Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.

  2013cited by this paper
• The multiobjective based design, synthesis and evaluation of the arylsulfonamide/amide derivatives of aryloxyethyl- and arylthioethyl- piperidines and pyrrolidines as a novel class of potent 5-HT₇ receptor antagonists.

  2012cited by this paper
• Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor-5-HT1A/5-HT2A/5-HT7 and D2/D3/D4-agents: the synthesis and pharmacological evaluation.

  2012cited by this paper
• Somatostatin antagonist potentiates haloperidol-induced catalepsy in the aged rat.

  2012cited by this paper
• Psychopharmacological treatment of schizophrenia: what do we have, and what could we get?

  2012cited by this paper
• In vitro metabolic stability and metabolite profiling of TJ0711 hydrochloride, a newly developed vasodilatory β-blocker, using a liquid chromatography-tandem mass spectrometry method.

  2011cited by this paper
• The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment

  2011cited by this paper
• Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis

  2010cited by this paper
• Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats.

  2010cited by this paper
• The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.

  2007cited by this paper
• From Haloquinolines and Halopyridines to Quinoline‐ and Pyridinesulfonyl Chlorides and Sulfonamides.

  2007cited by this paper
• Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol.

  2005cited by this paper
• Clozapine: neuroleptic-induced EPS and tardive dyskinesia

  2004cited by this paper
• Benzimidazole derivatives. Part 5: design and synthesis of new benzimidazole-arylpiperazine derivatives acting as mixed 5-HT1A/5-HT3 ligands.

  2004cited by this paper
• 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.

  2003cited by this paper
• Optimization of a Higher Throughput Microsomal Stability Screening Assay for Profiling Drug Discovery Candidates

  2003cited by this paper
• Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism.

  2002cited by this paper
• Medial Frontal Cortex Mediates Perceptual Attentional Set Shifting in the Rat

  2000cited by this paper
• Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6.

  1999cited by this paper
• The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?

  1999cited by this paper
• 1-aryl-4-[(5-methoxy-1,2,3, 4-tetrahydronaphthalen-1-yl)alkyl]piperazines and their analogues: influence of the stereochemistry of the tetrahydronaphthalen-1-yl nucleus on 5-HT1A receptor affinity and selectivity versus alpha1 and D2 receptors. 5.

  1999cited by this paper
• A User-Friendly Entry to 2-Iodoxybenzoic Acid (IBX)

  1999cited by this paper
• Increased ring closing metathesis activity of ruthenium-based olefin metathesis catalysts coordinated with imidazolin-2-ylidene ligands

  1999cited by this paper
• Specific Neuropsychological Deficits in Schizophrenic Patients with Preserved Intellectual Function

  1998cited by this paper
• Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice

  1997cited by this paper
• [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors

  1995cited by this paper
• Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.

  1994cited by this paper
• Organic Synthesis with .alpha.-Diazo Carbonyl Compounds

  1994cited by this paper
• Structure-activity relationship studies of CNS agents. Part 9: 5-HT1A and 5-HT2 receptor affinity of some 2- and 3-substituted 1,2,3,4-tetrahydro-beta-carbolines.

  1993cited by this paper
• WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors.

  1993cited by this paper
• Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.

  1989cited by this paper
• A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data.

  1988cited by this paper
• Antipsychotic drug doses and neuroleptic/dopamine receptors

  1976cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper
• A behavioral analysis of degree of reinforcement and ease of shifting to new responses in a Weigl-type card-sorting problem.

  1948cited by this paper

• Compound PZ-1262, a 4-isoquinoline-sulfonamide analog of Brexpiprazole, produces potential antidepressant, anxiolytic and procognitive effects in rodent models

  2025cites this paper
• Advances in Mechanochemical Methods for One‐Pot Multistep Organic Synthesis

  2025cites this paper
• Effects of ketamine on rat social behavior as analyzed by DeepLabCut and SimBA deep learning algorithms

  2024cites this paper
• First-in-Class Selenium-Containing Potent Serotonin Receptor 5-HT6 Agents with a Beneficial Neuroprotective Profile against Alzheimer’s Disease

  2024cites this paper
• Current development in sulfonamide derivatives to enable CNS-drug discovery.

  2024cites this paper
• Synthesis, computational and experimental pharmacological studies for (thio)ether-triazine 5-HT6R ligands with noticeable action on AChE/BChE and chalcogen-dependent intrinsic activity in search for new class of drugs against Alzheimer's disease.

  2023cites this paper
• Design, Synthesis and Biological Evaluation of Quinoline-8-Sulfonamides as Inhibitors of the Tumor Cell-Specific M2 Isoform of Pyruvate Kinase: Preliminary Study

  2023cites this paper
• Data Driven Computational Design and Experimental Validation of Drugs for Accelerated Mitigation of Pandemic-like Scenarios.

  2023cites this paper
• Hydrophobicity modulation via the substituents at positions 2 and 4 of 1,3,5-triazine to enhance therapeutic ability against Alzheimer's disease for potent serotonin 5-HT6R agents.

  2023cites this paper
• Multistep Mechanochemical Synthesis of PZ-1190, a Multitarget Antipsychotic Agent

  2023cites this paper
• Computational approaches for the design of novel dopamine D2 and serotonin 5-HT2A receptor dual antagonist towards schizophrenia

  2022cites this paper
• New N-aryl-N'-aryl-/(thio)ureido-/sulfamoylamino-derivatives of alkyl/alkylcarbamoyl piperazines: Effect of structural modifications on selectivity over 5-HT1A receptor.

  2022cites this paper
• 1-(Arylsulfonyl-isoindol-2-yl)piperazines as 5-HT6R Antagonists: Mechanochemical Synthesis, In Vitro Pharmacological Properties and Glioprotective Activity

  2022cites this paper
• An exit beyond the pharmacophore model for 5-HT6R agents - a new strategy to gain dual 5-HT6/5-HT2A action for triazine derivatives with procognitive potential.

  2022cites this paper
• Design, Synthesis, and Characterization of a Novel Fluoroprobe for Live Human Islet Cell Imaging of Serotonin 5‐HT1A Receptor

  2022cites this paper
• Design and Screening of New Lead Compounds for Autism Based on QSAR Model and Molecular Docking Studies

  2022cites this paper
• The Antidepressant-like Activity, Effects on Recognition Memory Deficits, Bioavailability, and Safety after Chronic Administration of New Dual-Acting Small Compounds Targeting Neuropsychiatric Symptoms in Dementia

  2022cites this paper
• N-Skatyltryptamines—Dual 5-HT6R/D2R Ligands with Antipsychotic and Procognitive Potential

  2021cites this paper
• Imidazopyridine-Based 5-HT6 Receptor Neutral Antagonists: Impact of N1-Benzyl and N1-Phenylsulfonyl Fragments on Different Receptor Conformational States.

  2021cites this paper
• Synthesis of Novel Pyrido[1,2-c]pyrimidine Derivatives with 6-Fluoro-3-(4-piperidynyl)-1,2-benzisoxazole Moiety as Potential SSRI and 5-HT1A Receptor Ligands

  2021cites this paper
• 2-Phenyl-1H-pyrrole-3-carboxamide as a New Scaffold for Developing 5-HT6 Receptor Inverse Agonists with Cognition-Enhancing Activity

  2021cites this paper
• Knowledge-Based Design of Long-Chain Arylpiperazine Derivatives Targeting Multiple Serotonin Receptors as Potential Candidates for Treatment of Autism Spectrum Disorder.

  2021cites this paper
• Single Molecule Non-cleavable Multiply Active Antibacterials

  2021cites this paper
• Design, Sustainable Synthesis and Biological Evaluation of a Novel Dual α2A/5-HT7 Receptor Antagonist with Antidepressant-Like Properties

  2021cites this paper
• Neuropathic pain-alleviating activity of novel 5-HT6 receptor inverse agonists derived from 2-aryl-1H-pyrrole-3-carboxamide.

  2021cites this paper
• Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT3 and 5-HT6 Receptor Antagonist with Antipsychotic and Procognitive Properties

  2021cites this paper
• The Phenoxyalkyltriazine Antagonists for 5-HT6 Receptor with Promising Procognitive and Pharmacokinetic Properties In Vivo in Search for a Novel Therapeutic Approach to Dementia Diseases

  2021cites this paper
• Curated Database and Preliminary AutoML QSAR Model for 5-HT1A Receptor

  2021cites this paper
• Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics

  2020cites this paper
• A dual-acting 5-HT6 receptor inverse agonist/MAO-B inhibitor displays glioprotective and pro-cognitive properties.

  2020cites this paper
• Recent development of piperazine and piperidine derivatives as antipsychotic agents.

  2020cites this paper
• Multi-targeted drug design strategies for the treatment of schizophrenia

  2020cites this paper
• Sustainable Synthesis of a Potent and Selective 5-HT7 Receptor Antagonist Using a Mechanochemical Approach

  2020cites this paper
• Chlorine substituents and linker topology as factors of 5-HT6R activity for novel highly active 1,3,5-triazine derivatives with procognitive properties in vivo.

  2020cites this paper
• Success in the Commercialization of Academic Life Science Discoveries in Poland – A Case Study from Jagiellonian University

  2020cites this paper
• Sulfonamide derivatives as multi-target agents for complex diseases.

  2019cites this paper
• Are the Hydantoin-1,3,5-triazine 5-HT6R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro

  2019cites this paper
• The chemistry of the carbon-transition metal double and triple bond: Annual survey covering the year 2018

  2019cites this paper
• The 1,3,5-Triazine Derivatives as Innovative Chemical Family of 5-HT6 Serotonin Receptor Agents with Therapeutic Perspectives for Cognitive Impairment

  2019cites this paper
• Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT1A receptor ligands.

  2019cites this paper
• Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT1A receptor ligands.

  2019cites this paper
• 5-HT1A receptor ligands and their therapeutic applications: review of new patents

  2018cites this paper
• Multi-Target Approach for Drug Discovery against Schizophrenia

  2018cites this paper
• Structural determinants influencing halogen bonding: a case study on azinesulfonamide analogs of aripiprazole as 5-HT1A, 5-HT7, and D2 receptor ligands

  2018cites this paper